Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2022-09-13 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding an inquiry about an increase in trading volume. The company states it has no information or pending announcements that could affect the stock price or volume. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is signed by the Company Secretary. The document is short (1079 characters) and serves as a regulatory communication or clarification rather than a financial report or announcement of results. It does not contain financial data, management changes, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2022-09-13 English
General updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI Listing Obligations and Disclosure Requirements. It is a regulatory compliance communication rather than a financial report, announcement of voting results, or management change. It does not contain financial data, audit information, or meeting materials. The document is short (1504 characters) and serves as a notification to the exchanges, fitting best under Regulatory Filings (RNS) as a general compliance announcement.
2022-08-24 English
Authorised Key Managerial Personnel to determine materiality of events/information
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI regulations. It is a regulatory compliance announcement rather than a financial report or detailed filing. The document is short (1504 characters) and does not contain financial data, audit information, or meeting materials. It does not announce voting results, dividends, or capital changes. It is best classified as a Regulatory Filing (RNS) since it is a compliance disclosure that does not fit other specific categories.
2022-08-24 English
General updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for an additional indication of a drug (Olaparib tablets). The content is an announcement of a regulatory approval related to the company's product, not a financial report, earnings release, or management discussion. It is a regulatory update informing the exchanges and public about a material event affecting the company. The document length is short (1737 characters) and does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-19 English
This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission from the Drugs Controller General of India for a new drug indication. It is an announcement of a regulatory approval related to product marketing, not a financial report, earnings release, or management discussion. The document is short (1737 characters) and serves as an official regulatory announcement to the exchanges. It does not contain financial data, management changes, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-19 English
In continuation of our earlier announcement dated December 30, 2021, we wish to inform you that at the Company's Annual General Meeting held on August 8, 2022, the Shareholders have approved ....
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a new Independent Director at the Annual General Meeting held on August 8, 2022. It includes details about the director's profile, term of appointment, and compliance with regulatory requirements. The content focuses on management changes rather than financial results or reports. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but an announcement of a management change.
2022-08-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.